Visiongain has published a new report entitled Antiviral Drugs 2022-2032. It includes profiles of Antiviral Drugs and Forecasts Market Segment by Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others), Market Segment by Application (HIV/AIDS, Influenza, Hepatitis, Herpes, Others), Market Segment by End User (Hospitals, Clinic, Others), Market Segment by Age Group (Adult, Pediatric, Geriatric), Market Segment by Type (Branded Drugs, Generic Drugs), plus COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped), Profiles of Leading Companies, Region and Country.
The antiviral drugs market was valued at US$38.96 billion in 2021 and is projected to grow at a CAGR of 3.49% during the forecast period 2022-2032.
Favourable Initiatives Taken by Government Bodies to Manage Viral Diseases to Foster Market Progression
The management of viral infections is anticipated to benefit from positive government actions conducted to combat and treat viral diseases. The U.K. government, for instance, has established an antiviral task force to look into cures for SARS-CoV-2 infection in residential settings. It will aid in preventing infection and reducing the impact of future SARS-CoV-2 virus strains. Additionally, the US government is spending almost US$3 billion to speed up the discovery of antiviral medications to treat COVID-19 and other viral illnesses.
The increase of COVID-19 cases and the robust pipeline of medicines are anticipated to have a positive effect on market expansion. The WHO estimates that there were 217.56 million confirmed cases of COVID-19 as of September 1, 2021, with 4.52 million deaths being reported. For instance, BAL Pharma introduced the antiviral medicine BALflue in May 2021. It is based on the Favipiravir formula and is used to treat people who have mild to moderate Covid-19 infection as well as 53 other influenza viruses. The COVID-19 pandemic is expected to boost market growth overall, but it has had a negative impact on the consumption of antiviral drugs from other applications due to supply chain disruption and restricted access to healthcare services during the total lockdown.
Download Exclusive Sample of Report
How has COVID-19 had a Significant Impact on the Antiviral Drugs Market?
The rising prevalence of viral infections & the presence of a potential pipeline for the treatment of HIV infection are anticipated to drive market growth over forecast period from 2022 to 2032. Antiviral medications have been in high demand throughout the pandemic, which may be what propels the market expansion along with the rising COVID-19 burden. For instance, Dr. Reddy’s Laboratories Ltd. reported that the single-shot Sputnik Light vaccine received permission from the Drugs Controller General of India (DCGI) for restricted usage in emergency situations in India. While Gilead Sciences announced US$24 billion in funding in March 2022 to support local areas most affected by the HIV epidemic and COVID-19 pandemic, eliminate health inequities, increase access to high-quality healthcare, expand medical education, and cut healthcare costs. Thus, widespread R&D activities taking place on biologics for the treatment of COVID-19 are likely to drive the growth of the antiviral drug market in the near future.
How will this Report Benefit you?
Visiongain’s 285-page report provides 126 tables and 196 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the antiviral drugs market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Antiviral Drugs. Get financial analysis of the overall market and different segments including drug class, application, end user, age group, type and capture higher market share. We believe that there are strong opportunities in this fast-growing antiviral drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the Current Market Drivers?
Research & Development Activities to Boost Market Growth
The business expansion will be stimulated by widespread R&D efforts to battle the recently revealed COVID-19 pandemic and other ongoing viral illnesses. Numerous pharmaceutical companies’ substantial investments in R&D initiatives will present the antiviral medicine industry with numerous growth potential in the ensuing years. A number of significant market participants are actively engaged in the development of innovative drug therapies to treat infectious diseases, which will increase the market’s potential for growth. In addition, a number of national organizations are heavily funding R&D initiatives to reduce the burden of disease.
To prioritize and speed the development of COVID-19 therapies, the National Institute of Allergy and Infectious Diseases (NIAID) & NIH Institutes and Centers collaborated in 2020. There will be more product introductions in the future as a result of these research centers’ intense attention on SARS-CoV-2 and other viruses with pandemic potential such bunyaviral, paramyxoviruses, togaviruses, picornaviruses, and filoviruses. Additionally, certain governments and other private groups have put in place information campaigns regarding the availability of cutting-edge treatments for STDs.
Growing Burden of Viral Diseases to Spur the Demand for Antiviral Drugs
The most prevalent viral infection on the planet today is HIV. The rate of HIV diagnosis has increased as a result of using demographic and biological data for better surveillance of the illness. In 2020, the World Health Organization estimates that 37.7 billion people worldwide would have HIV, and 680,000 people would pass away from the condition. At the end of 2021, there were roughly 38.4 million HIV-positive individuals worldwide, and 1.5 million persons acquired the virus that year. Globally, 650 000 persons passed away in 2021 due to HIV-related causes. As a result, the need for targeted and specific treatment plans is growing due to the virus’s increasing prevalence, which is boosting the market for antiviral drugs. As a result, increased product accessibility for advanced therapies, such as antiretroviral therapy, in developed nations to address disease load will move the total antiviral medications market forward.
Additionally, the need for antiviral therapies is growing due to the flu’s rapid diagnosis and rising global occurrence rate. The number of persons suffering from influenza and other viral respiratory infections is on the rise, notably during the COVID-19 pandemic. Viral infectious diseases are spreading quickly due to increasing human mobility, greater trade and tourism, and altered geographic distribution of disease vectors.
For instance, According to CDC data, between October 3, 2020, and July 24, 2021, 1.3 million specimens tested by clinical laboratories and reported to the US Centers for Disease Control and Prevention (CDC) included 2136 influenza virus positive specimens and 748 influenza-related deaths. Additionally, The COVID-19 epidemic poses a major global health threat. The prompt spread was facilitated by air travel although rigorous travel bans, and lockdowns were able to slow down the spread.
Download Exclusive Sample of Report
Where are the Market Opportunities?
Robust Investment by Pharmaceutical Organizations to Boost Market Growth
Numerous pharmaceutical companies are investing heavily in research and development efforts, which will provide tremendous growth potential for the antiviral medications industry in the next years. Several prominent market companies are actively participating in the development of novel medication treatments to treat infectious diseases, which would boost the industry’s potential for growth. Furthermore, some national organisations are heavily investing in R&D to reduce disease burdens.
For instance, as a part of its COVID-19 response effort, the Bill & Melinda Gates Foundation on Oct 2021 announced a donation of up to US$120 million to speed access to the investigational antiviral medication molnupiravir for lower-income nations. The funds will be distributed after consulting with partners and will assist a variety of initiatives needed to create generic versions of the medication that Merck & Co. and Ridgeback Biotherapeutics are working on together.
By assisting R&D, regulatory work, at-risk manufacturing, and product delivery, the foundation has been working to enhance access to COVID-19 vaccines, treatments, and testing ever since the pandemic began, investing US$1.9 billion in financing in that time.
Moreover, the Department of Health and Human Services announced that the US government is spending more than $3 billion to speed up the development and production of antiviral medications to treat Covid-19 (HHS). The plan allotted nearly US$1 billion for preclinical and clinical evaluation, nearly US$700 million for development, and more than US$300 million for research and lab support via the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA). In addition, certain governments and private organisations have launched public awareness campaigns about the availability of improved medicines for sexually transmitted illnesses which is anticipated to fuel market growth over the forecast period.
The major players operating in the antiviral drugs market are Johnson & Johnson Services, Inc., Merck KGaA, GlaxoSmithKline plc., Novartis AG, F. Hoffmann-La Roche Ltd, AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, Cipla Inc., Abbott, Viatris (Mylan N. V.), Sun Pharmaceutical Industries Ltd., Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
In March 2022, AbbVie & Scripps Research collaborated to develop potential novel, direct-acting antiviral treatments for COVID-19.
In January 2022, for the treatment of COVID-19, Aurobindo Pharma Limited introduced molnupiravir under the trade name Molnaflu in India. This is projected to strengthen company’s product portfolio over the forecast period.
To access the data contained in this document please email firstname.lastname@example.org
Avoid missing out by staying informed – order our report now.
To find more Visiongain research reports on the Pharma sector, click on the following links:
RNA Based Therapeutics and Vaccines Market Report 2022-2032
Mesenchymal Stem Cells Market Report 2022-2032
Precision Cancer Diagnostic Test Market Report 2022-2032
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: email@example.com
Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicated market research reports offer a bespoke piece of market intelligence customised to your very own business needs.
PR at Visiongain Reports Limited
Tel: + 44 0207 336 6100
The FDA has granted a Complete Response Letter (CRL) to Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) marketing application seeking approval for poziotinib for previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 20 insertion mutations. The FDA issued a CRL indicating that the poziotinib application cannot be approved in its present form. Based on the CRL, the company would have to generate additional data, including a randomized controlled stu
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Until that day, companies in the healthcare sector that can stay ahead of the curve will continue to thrive. Although this market is competitive, the company made its name by targeting the life sciences industry. In other words, Veeva Systems is a specialist, not a generalist.
Medical researchers believe they've finally found the cause of Bruce Lee's mysterious death almost 50 years ago.
Former surgeon general Jerome Adams and his wife, Lacey, often find themselves talking about what they have named the "Trump Effect." It followed them from Washington to their home in the Indianapolis suburbs. They felt it when he was exploring jobs in academia, where he would receive polite rejections from university officials who worried that someone who served in the administration of the former president would be badly received by their left-leaning student bodies. They felt it when corporat
Toronto Maple Leafs great Borje Salming, who passed away on Thursday from nervous disease amyotrophic lateral sclerosis (ALS), succumbed unusually quickly to the disease less than four months after diagnosis, his doctor told Swedish broadcaster SVT. Salming died at the age of 71 and became the first Swedish player inducted into the Hockey Hall of Fame.
Covid-19 is flaring up in China, despite it having some of the toughest lockdown rules in the world.
Steven Lome, a cardiologist and distance runner, had never witnessed anybody experience a cardiac arrest during a road race. Nor did he expect to use his professional skills outside work. But while running the Monterey Bay Half Marathon in California on Nov. 13, Lome saw not one, but two runners collapse on the course, and he performed cardiopulmonary resuscitation (CPR) on both. The two runners, men in their 50s and 60s, survived and are expected to make full recoveries, Lome recounted in a Twi
STORY: At a hospital in Kenya's capital Nairobi, surgeons are preparing a patient for reconstructive surgery.She is a survivor of female genital mutilation, or FGM, and requested anonymity."I was nine years old. I did not know about anything, I was just told that I will be taken for a, like something to make me a complete woman."Instead, the police officer says she was left feeling incomplete.That's why she was one of around 60 women who recently came forward for free clitoris reconstruction surgery."This surgery is very important to me because being a woman who has undergone FGM, I basically feel like I am incomplete. There are things that other girls enjoy that I don't. It has really put my esteem so down."FGM is practiced in 30 countries in Africa, the Middle East and Asia.It involves the partial removal of the external or visible part of the clitoris.U.S. surgeon Dr Marci Bowers was brought in by Clitoraid for the two-week surgery initiative.She has operated on hundreds of Kenyan women during two previous visits.She said the clitoris is around 11 centimeters long with much of it inside the body. She described FGM as like "cutting the tip of the iceberg"."But, beneath the surface is the iceberg and so, what we do in our surgeries is bring the 'iceberg' or clitoral body to the surface so that it can be realized and sensate."According to the United Nations, one in five Kenyan women and girls aged between 15 and 49 have undergone FGM.Bowers said her patients most often describe the reconstruction as "life-changing" and say it has given them a chance to reclaim their womanhood.
The XBB variant has climbed to 3.1% of new COVID cases nationwide, the CDC now estimates.
Yahoo Finance’s Jared Blikre is joined by Surgeon, Entrepreneur, Financial Literacy Enthusiast, as they discuss bigger picture issues, take on crypto, and more.
A Minnesota woman allegedly stole her son's blood and abused her other two children, authorities said. She now faces charges of child torture, stalking.
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is proud to announce the Health Canada license of the Forma-I to address the symptoms of dry eye disease due to Meibomian gland dysfunction (MGD). Forma-I is intended for use in the periorbital area and eyelids and relieves inflammation of meibomian glands and eye irritation.
Professor John Oxford, professor of virology at Queen Mary University, said an experimental vaccine published in a US study on Thursday was a 'huge breakthrough'.
(Bloomberg) — The American outbreak of avian influenza is officially the worst on record with 50.54 million dead birds, according to the US Department of Agriculture.Most Read from BloombergTiantian Kullander, Co-Founder of Crypto Firm Amber, Dies at 30A Rival’s Misstep Helped Anwar Finally Land Malaysia’s Top JobUS Shoppers Kick Off Holiday Season With a Muted Black FridayAdobe Sees Up to $9.2 Billion in E-Commerce: Black Friday UpdateUS Bans Huawei, ZTE Telecom Equipment on Data-Security Risk
One person died and another was injured in a Thursday morning fire in Dunedin. Dunedin Fire Rescue said the first call about the fire came in at 9:10 a.m.
It’s estimated that 55 million Americans will travel over the Thanksgiving holiday. That’s the highest level since the pandemic began and the third-highest since AAA began tracking the holiday in 2000. At the same time, Covid cases have been steadily rising nationally, with the most recent 24-hour total being 111,386, according to Johns Hopkins. That’s […]
Montana Erickson, 17, died three days after the accident
Preparing children for the loss of a loved one is incredibly hard, but also incredibly important.
An adorable encounter between two fitness enthusiasts has blossomed into a regular collaboration of wholesome content on social media. Daniel Kim, a personal trainer in Orange County who posts fitness-related content on his TikTok account @deekimm, was recording a workout session back in September when a woman named Cheri accidentally walked into his shot. Cheri then approaches Kim and explains to him that she was distracted as she was admiring his arms.